Differences between oral cancer and cancers of the pharynx and larynx on a molecular level

Oncology Letters

Volumn 3, Issue 1, 2012, Pages 238-243

  Shiga, Kiyoto ^a   Ogawa, Takenori ^b   Katagiri, Katsunori ^a   Yoshida, Fumiaki ^b   Tateda, Masaru ^b   Matsuura, Kazuto ^c   Kobayashi, Toshimitsu ^b  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c Miyagi Cancer Center   (Japan)

Author keywords

DNA methylation; Gender; Head and neck cancers; Location of the tumor; Loss of heterozygosity

Indexed keywords

PROTEIN P16;

ADULT; ALLELE; ARTICLE; CANCER PATIENT; CARCINOGENESIS; CHEEK MUCOSA; CHROMOSOME 17P; CHROMOSOME 3P; CHROMOSOME 9P; CONTROLLED STUDY; DISEASE SEVERITY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE LOSS; GENETIC ANALYSIS; GINGIVA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; HYPOPHARYNX; LARYNX CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; PHARYNX CANCER; POLYMERASE CHAIN REACTION; PROMOTER REGION; SQUAMOUS CELL CARCINOMA; TONGUE CANCER; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

EID: 84855221343     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.451     Document Type: Article

References (23)

1. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Barterk J and Sidransky D: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56: 3630-3633, 1996.
2. Gonzalez MV, Pello MF, Lopez-Larrea C, Suarez C, Menendez MJ and Coto E: Deletion and methylation of the tumor suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma. J Clin Pathol 50: 509-512, 1997.
3. El-Naggar AK, Lai S, Clayman G, Lee J-K J, Luna MA, Goepfert H and Batsakis JG: Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous cell carcinoma. Am J Pathol 151: 1767-1774, 1997.
4. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG and Sidransky D: Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60: 892-895, 2000.
5. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M and Kelsey KT: Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21: 4231-4236, 2002.
6. Weber A, Wittekind C and Tannapfel A: Genetic and epigenetic alterations of 9p21 gene products in benign and malignant tumors of the head and neck. Pathol Res Pract 199: 391-397, 2003.
7. Ai L, Stephenson KK, Ling W, Zuo C, Mukunyadzi P, Suen JY, Hanna E and Fan C-Y: The p16 (CDKN2a/INK4a) tumor- suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases. Mod Pathol 16: 944-950, 2003.
8. Maruya S, Issa J-PJ, Weber RS, Rosenthal DI, Haviland JC, Lotan R and El-Naggar AK: Differential methylation status of tumor-associated genes in head and neck squamous cell carcinoma: incidence and potential implications. Clin Cancer Res 10: 3825-3830, 2004.
9. Puri SK, Si L, Fan C-Y and Hanna E: Aberrant promoter hypermethylation of multiple genes in head and neck squamous cell carcinoma. Am J Otolaryngol 26: 12-17, 2005.
10. Shiga K, Matsuura K, Tateda M, Saijo S, Ogawa T, Miyagi T and Kobayashi T: Allelic loss correlated with tissue specificity in head and neck squamous cell carcinomas and the clinical features of patients. Tohoku J Exp Med 204: 163-172, 2004.
11. Shiga K, Yamamoto H and Okamoto H: Isolation and characterization of the human homologue of rig and its pseudogenes: The functional gene has features characteristic of housekeeping genes. Proc Natl Acad Sci USA 87: 3594-3598, 1990.
12. Shiga K, Shiga C, Sasano H, Miyazaki S, Yamamoto T, Yamamoto M, Hayashi N, Nishihira T and Mori S: Expression of c-erbB-2 in human esophageal carcinoma cells: overexpression correlated with gene amplification or with GATA-3 transcription factor expression. Anticancer Res 13: 1293-1302, 1993.
13. Van der Riet P, Nawroz H, Hruban RH, Corio R, Tokino K, Koch W and Sidransky D: Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 54: 1156-1158, 1994.
14. Zhang S-Y, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA and Goodrow TL: Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck: Cancer Res 54: 5050-5053, 1994.
15. Nawroz H, van der Riet P, Hruban RH, Koch W, Ruppert JM and Sidransky D: Allotype of head and neck squamous cell carcinoma. Cancer Res 54: 1152-1155, 1994.
16. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993.
17. Serrano M, Lee H-W, Chin L, Cordon-Cardo C, Beach D and Depinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-37, 1996.
18. Kamb A, Gruis NA, Weaver-Fejdhaus J, Lin Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE and Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994.
19. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
20. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, et al: Frequency of homozygous deletion at p16/CDK2 in primary human tumors. Nat Genet 11: 210-212, 1995.
21. Lydiatt WM, Murty VV, Davidson BJ, Xu L, Dyomina K, Sacks PG, Schantz SP and Chaganti RS: Homozygous deletions and loss of expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors. Genes Chromosomes Cancer 13: 94-98, 1995.
22. Herman JG, Merlo A, Mao L, Lapidus RG, Issa J-PJ, Davidson NE, Sidransky D and Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995.
23. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D: 5' CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692, 1995.